---
title: "Non-Inferiority Trial 실전"
author: "Jinseob Kim (차라투)"
date: "2023-06-24"
format:
  revealjs: 
    theme: default
    logo: https://raw.githubusercontent.com/jinseob2kim/lecture-general/master/docs/APPFGH2022/zarathu_eng.png
    footer: "www.zarathu.com"
    self-contained: false
    chalkboard: 
      buttons: false
    preview-links: true
    show-notes: false
    slide-number: false
    width: 1600
    height: 900
editor: visual
subtitle: "KSIC Summer Conference 2023"
---


## Contents

1. 샘플수 계산

2. 비열등성 마진(margin)

3. 분석결과 제시


## References

1. [LOADSTAR](https://jamanetwork.com/journals/jama/article-abstract/2802214)(JAMA `23): YUHS

2. [RACING](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00916-3/fulltext)(Lancet `22): YUHS

3. [FLAVOUR](https://www.nejm.org/doi/full/10.1056/NEJMoa2201546)(NEJM `22): SNU

4. [RENOVATE-COMPLEX-PCI](https://www.nejm.org/doi/full/10.1056/NEJMoa2216607)(NEJM `23): SMC


# 샘플 수 계산 


## **Proportion vs Survival** based approach

[Proportion](http://powerandsamplesize.com/Calculators/Test-Odds-Ratio/Non-Inferiority-or-Superiority)

- Event rate 만 이용. 
- Racing, LOADSTAR, FLAVOUR

[Survival](https://nshi.jp/en/js/twosurvyrni/) 

- Event rate, accural/FU time 고려
- RENOVATE-COMPLEX-PCI


## Racing

::: columns
::: {.column width="60%"}
![](img/sample_racing.png)

:::

::: {.column width="40%"}
![](img/racing_sample.png)
:::
:::


## LOADSTAR

::: columns
::: {.column width="60%"}
![](img/sample_loadstar.png)

:::

::: {.column width="40%"}
![](img/loadstar_sample.png)
:::
:::


## FLAVOUR

::: columns
::: {.column width="35%"}
![](img/sample_flavour.png)

:::

::: {.column width="65%"}
![](img/flavour_sample.png)
:::
:::


## RENOVATE-COMPLEX-PCI

::: columns
::: {.column width="35%"}
![](img/sample_reno.png)

:::

::: {.column width="65%"}
![](img/reno_sample.png)
:::
:::


## Use `gsdesign` packages

::: columns
::: {.column width="60%"}
```{r, echo=T, eval = F}
library(gsDesign)
## Annual incidence
Pc <- 0.06; Pt <- 0.036
## Hazard rate: S(t) = exp(-lambda * t)
lambda_c <- -log(1 - Pc); lambda_t <- -log(1 - Pt)
hr <- lambda_t/lambda_c

nSurv(
  lambdaC = lambda_c,  # Hazard rate of control group
  hr = hr,             # Alternative hypothesis
  hr0 = 1,             # Null hypothesis
  T = 4,               # Total study period              
  R = 3,               # Accrural period 
  minfup = 1,          # 4- 3  
  beta = 0.1,       
  alpha = 0.025,       # 1-sided
  eta = 0,             # Annual drop out rate
  ratio = 2)           # Randomization ratio, experimental/control
```
:::

::: {.column width="40%"}

```{r}
library(gsDesign)
## Annual incidence
Pc <- 0.06; Pt <- 0.036
## Hazard rate: S(t) = exp(-lambda * t)
lambda_c <- -log(1 - Pc); lambda_t <- -log(1 - Pt)
hr <- lambda_t/lambda_c

nSurv(
  lambdaC = lambda_c,  # Hazard rate of control group
  hr = hr,             # Alternative hypothesis
  hr0 = 1,             # Null hypothesis
  T = 4,               # Total study period              
  R = 3,               # Accrural period 
  minfup = 1,          # 4- 3  
  beta = 0.1,       
  alpha = 0.025,       # 1-sided
  eta = 0.02,             # Annual drop out rate
  ratio = 2            # Randomization ratio, experimental/control
)
```

:::
:::


# 비열등성 마진(margin)


## Statistical & Clinical

- 차이가 없을 때 p < 0.05 나와야 함. 

- 임상적으로 허용가능한 범위

![https://www.nejm.org/doi/full/10.1056/NEJMra1510063](https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/2017/nejm_2017.377.issue-14/nejmra1510063/20180122/images/img_medium/nejmra1510063_f1.jpeg)


## LOADSTAR 리비전

An unclear rational for a non-inferiority trial at all, i.e., **why is the targeted approach considered less burdensome** and therefore advantageous if equally effective?

- "target이 burden이 작기때문에 non-inferiority를 증명하는 것만으로 충분하다는 논리" 에 대한 의문.
- targeted  approach 가 왜 burden이 작냐는 질문에 답변 필요


**Poor justification for the 3% non-inferiority margin**, since that would correspond to a NNT of about 33, which would seem to justify the use of fixed high-intensity therapy if that were the true difference

- margin 3% 너무 큰거 아니냐?
- 실제로 3% 차이면 기존 fixed therapy가 더 나은것이라는 의견. 임상적 설명 필요.  




# 분석결과 제시

## Difference with upper 97.5(or 95)% CI

```{r, echo=T}
library(survival)
fit <- summary(survfit(Surv(time, status) ~ sex, data = colon), times = 365)

## Surv2 - Surv1 = Inci1 - Inci2
kmdiff <- diff(1 - fit$surv) 

## Var(Surv1 + Surv2) = Var(Surv1) + Var(Surv2)
sediff <- sqrt(sum(fit$std.err^2))

c(Diff = kmdiff, LCI = kmdiff - 1.96 * sediff, UCI = kmdiff + 1.96 * sediff)
```
Upper limit < margin 이면 유의한 결과.

```{r, echo=T}
margin <- 3
pv <- 1 - pnorm(abs((margin - kmdiff)/sediff))
pv
```


## KM estimate vs Proportion

KM 발생률을 대부분 썼으나 proportion 을 요구하는 경우도 있음. 

- RACING: Kaplan-meier estimate 쓰지말고 그냥 proportion 써라.

![](img/kmracing.png){width=50%}

- KM: 9.3 vs 10.3% -> **9.1 vs 9.9% (Event/N)**  


## CI for proportion difference

RACING: Wilson CI 써라 

- For the primary and key secondary outcome I would question if the **Normal approximation does not hold**. 

- 보수적인 지표

![](img/wilson.png){width=50%}


## Primary outcome만 비열등성 검정 

::: columns
::: {.column width="65%"}
![](img/tb_loadstar){width=80%}

:::

::: {.column width="35%"}
>Analyses of **secondary endpoints were not adjusted for multiplicity**, and findings should be interpreted as exploratory because of the potential for type I error
:::
:::


## LOADSTAR 리비전

Some lack of clarity regarding the exact statistical test used to establish the confidence interval around the difference in event rate

- Kaplan meier 방법으로 두 군의 Incidence  값과 standard error 를 각각 얻습니다.
- 이것을 이용해  difference 값과 upper 97.5% 신뢰구간을 구합니다. 
- 본 연구에서 Cox 분석은 없습니다.

Uncertainty regarding the responsiveness of the endpoint over the duration of follow up.

- 3년 F/U 기간 이후엔 어떠냐. 더 오래 관찰해야할 수도 있다는 의견.
- 3년 이후 outcome이 혹시 있다면 보여주고, 아니면 3년관찰로 충분히 의미있다고 설명. 


## HR 필요?

**LOADSTAR**: HR 지표가 아예 없음. Rate difference 만 보여줌. 

- 따라서 Cox 분석도 없음. **simple is the best**

**RENOVATE-COMPLEX-PCI**: 반대로 고급분석요구 

- Stratified Cox: 각 병원의 고유 특성을 고려
- Competing risk analysis: Other cause death 고려


## RENOVATE-COMPLEX-PCI 리비전

1. P10 L53. Earlier you stated that the randomization was stratified by clinical presentation and by treatment center. Did you apply a stratified logrank test to incorporate this design feature, and include these covariates in the Cox model estimation? Please clarify.

- 다기관 고려한 stratified 분석해라. 
- **R coxph 식에 `+strata(기관변수)` 추가 **

```{r, echo=T, eval=F}
coxph(Surv(time, status) ~ group + strata(hospital), data = data)
```

## RENOVATE-COMPLEX-PCI 리비전

3. P13 L36-39. The analyses that properly account for competing risks should be the primary analyses here; the standard K-M or Cox model estimates that ignore competing risks are incorrect. Please describe the method used to accommodate competing risks in the methods section, and present these results as the primary analysis.

-> Competing risk analysis 를 primary로 해라 

::: columns
::: {.column width="40%"}
```{r}
library(jskm);library(survival)
colon$status2 <- colon$status
colon$status2[1:400] <- 2
colon$status2 <- factor(colon$status2)
fit2 <- survfit(Surv(time,status2)~rx, data=colon)
jskm(fit2, mark = F, surv.scale = "percent", table = T, status.cmprsk = "1")

```
:::

::: {.column width="60%"}
```{r, echo=T, eval=F}
library(jskm);library(survival)
colon$status2 <- colon$status
colon$status2[1:400] <- 2
colon$status2 <- factor(colon$status2)
fit2 <- survfit(Surv(time,status2)~rx, data=colon)
jskm(fit2, mark = F, surv.scale = "percent", table = T, status.cmprsk = "1")

```
:::
:::


## RENOVATE-COMPLEX-PCI 리비전

2. P13 L32. What was the “per protocol” analysis? This is the first time this is mentioned; it should be explained in the methods section. Please also note that per protocol analyses that are based on an analysis dataset constructed by **eliminating cases based on post-randomization events (e.g., treatment crossover) are generally biased and are not allowed**. More principled methods of analyzing a trial subject to non-adherence should be used. See for instance Hernan and Robins, NEJM 2017; 377: 1391-1398.

-> Per-protocol 하면서 연구디자인 깨지는거 아니냐?

Per-protocol: Image군에서 Angio, Angio군에서 Image를 한 환자를  Protocol violation이라고 미리 정의.


## PP scenario


<center>
<img src="img/nejmpp.png" width=50%></a>
</center>



A는 OK, B -> C -> D 로 갈수록 복잡한 보정 필요.

* A 에 해당함을 주장.




# 감사합니다


